UNSPSC 51281626: Tobramycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VZ8RRZ51VK, chemically known as tobramycin, free base but generally known as tobramycin, which bears US NIH Compound Identifier 5496. European Medicines Agency schedules Tobramycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11134MIG.

UNSPSC 51281626 Tobramycin is a Commodity code that nominally describes a specific antibiotic pharmaceutical product, but recent state and local opportunities tagged under this code show little direct activity for tobramycin itself. Instead, the opportunities reflect broader pharmaceutical procurement across generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs. State and local governments—including county health departments, city emergency services, state health commissions, and cooperative purchasing alliances—are sourcing pharmaceuticals and medical supplies through IFBs, RFPs, and RFIs that prioritize volume pricing, wholesaler relationships, compliance with cGMP and Drug Supply Chain Security Act standards, and flexible pricing models. The work involves competitive bidding on fixed-price or net-price pharmaceutical contracts, often with quarterly or annual delivery schedules to multiple facilities, and increasingly includes direct contracting arrangements between state agencies and manufacturers to bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity spans Florida, Texas, and Minnesota through a cooperative purchasing vehicle. Seminole County, Florida issued IFB 60459723LAS in June 2026 for naloxone and drug deactivation systems (1,900 units and 800 systems annually, due July 26, 2023). The City of Tampa issued IFB 26P00145 in March 2026 for medical and first aid supplies ($700,000 estimated value) designated as a sheltered market opportunity for certified Small Local Business Enterprises. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer pharmacy programs outside traditional PBM channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, requiring 3 percent administrative fees and compliance with authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson.